Fezolinetant

Tier C — Watch / trade

Fezolinetant

Ogeda SA

Originator

2023

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：NK3R

Brand：VEOZAH

Indications (approved)：Vasomotor symptoms, Hot flushes

Regional status

Approved

2023-05-12

Approved

2023-12-07

China

Phase III

2020-03-17

Japan

Phase III

2024-02-16

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Fezolinetant?

Approved indications include: Vasomotor symptoms, Hot flushes.

When does the Fezolinetant patent expire?

No public expiry year is available for Fezolinetant yet; this page updates once verified.

How do I get a quote for Fezolinetant intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27